Despite Recent Declines, I’m Still Buying Royal Dutch Shell Plc And GlaxoSmithKline plc

The time to buy Royal Dutch Shell Plc (LON: RDSB) and GlaxoSmithKline plc (LON: GSK) is now, says this Fool.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Sometimes the market presents an opportunity that’s too hard to pass up. And amidst the recent market chaos, two once-in-a-lifetime opportunities have emerged in the form of Royal Dutch Shell (LSE: RDSB) and GlaxoSmithKline (LSE: GSK).

Market sentiment couldn’t be more negative for these two companies. For example, over the past six months, Shell and Glaxo’s shares have slumped 22.3% and 13.1% respectively. Shell’s shares printed a new five-year low at the end of August. 

5 Stocks For Trying To Build Wealth After 50

One notable billionaire made 99% of his current wealth after his 50th birthday. And here at The Motley Fool, we believe it is NEVER too late to start trying to build your fortune in the stock market. Our expert Motley Fool analyst team have shortlisted 5 companies that they believe could be a great fit for investors aged 50+ trying to build long-term, diversified portfolios.

Click here to claim your free copy now!

However, based on historic data, current trends and management predictions, these declines look to be overdone. 

Oil issues 

Shell’s shares have fallen in line with the price of oil, and many of the company’s peers have also seen their shares slump to five-year lows during the past few weeks. 

But these declines could present an opportunity for investors. Indeed, Shell is still profitable, has a rock-solid balance sheet and is slashing costs to improve margins. What’s more, Shell remains one of Europe’s largest refiners, and one of the world’s largest oil traders. First-half refining and marketing profits jumped 93% year-on-year to $5.6bn. 

Still, many investors are concerned about the state of Shell’s dividend. The company’s cash flow from operating activities slumped 42% to $13.2bn during the first half of the year, barely covering capital spending of $12.4bn. As a result, Shell’s dividend bill of $5.2bn in the first-half was paid with debt. 

Nevertheless, while the figures may suggest that Shell will have to cut its dividend payout, the company has the capacity to maintain its payout at present levels in the short term as earnings fall. Shell’s net gearing is 14.3%, and the company is selling off some assets to boost its credit profile. Also, capital spending is set to fall during the next few years as the company adjusts to the oil price environment. 

So overall, Shell’s lofty dividend yield of 7.5% looks to be safe for the time being. 

Out of favour

It seems as if Glaxo has become the FTSE 100‘s most disliked company. Since the end of April, the company’s shares have lost a fifth of their value as the City has expressed concern about the sustainability of the group’s dividend payout. 

But the City’s negative views run contrary to the projections put out by Glaxo’s own management. 

Glaxo’s management has stated that the company’s dividend payout will be maintained at 80p per share for the next few years. While I’m always sceptical about management forecasts, I’m inclined to believe that this will be the case. Glaxo’s management has a reputation to uphold, and there’s nothing more damaging to a reputation than going back on a commitment to maintaining a dividend. 

While City projections estimate that Glaxo’s dividend payout won’t be covered by earnings per share this year, figures suggest the payout will be covered by earnings next year.

Moreover, based on the number of new treatments Glaxo currently has under various stages of development, management believes that the group can steadily grow earnings by the mid-to-high single digits” from 2016 to the end of the decade, further improving dividend cover.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Rupert Hargreaves owns shares of GlaxoSmithKline and Royal Dutch Shell B. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

man in shirt using computer and smiling while working in the office
Investing Articles

Is Scottish Mortgage Investment Trust now a bargain growth stock?

The Scottish Mortgage Investment Trust share price has plummeted nearly 50% from its 52-week high. Is this a great opportunity…

Read more »

A couple celebrating moving in to a new home
Investing Articles

2 key stock picks for reliable passive income

I’m looking at stocks that can deliver reliable passive income to complement my growth picks, and I think I’ve found…

Read more »

A Rolls-Royce employee works on an engine
Investing Articles

In penny stock territory, is the Rolls-Royce share price set to soar?

The Rolls-Royce share price has sunk recently, falling into penny stock territory. But with flying hours recovering, is it too…

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Lloyds shares drop 20% in 4 months. Should I buy now?

Lloyds shares have lost a fifth of their value since peaking on 17 January this year. But after rebounding from…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

As the stock market recovery stalls, should I wait to buy?

Has the stock market recovery run out of steam? If so, what does that mean for our writer's portfolio? Here…

Read more »

Diagonal chain made of zeros and ones. Cryptocurrency and mining.
Investing Articles

At 55p, is the Argo Blockchain (LON:ARB) share price too cheap to miss?

With a low P/E ratio and strong financial results, could the Bitcoin miner be good value for money?

Read more »

macro shot of computer monitor with FTSE 100 stock market data in trading application
Investing Articles

Here are 2 recession-proof FTSE stocks!

In the face of current economic uncertainty and fears of a looming recession, this Fool identifies two recession-proof FTSE stocks.

Read more »

British Pennies on a Pound Note
Investing Articles

Here is 1 penny stock primed to benefit from the construction boom!

Jabran Khan delves deeper into a penny stock that he believes could benefit from the construction boom, and explains why…

Read more »